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ABSTRACT
Bovine leukemia virus expression relies on its chro-
matin organization after integration into the host cell
genome. Proviral latency, which results from tran-
scriptional repression in vivo, represents a viral
strategy to escape the host immune system and
likely allows for tumor progression. Here, we
discriminated two types of latency: an easily
reactivable latent state of the YR2 provirus and a
‘locked’ latent state of the L267 provirus. The de-
fective YR2 provirus was characterized by the
presence of nuclease hypersensitive sites at
the U3/R junction and in the R/U5 region of the
50-long terminal repeat (50-LTR), whereas the L267
provirus displayed a closed chromatin configur-
ation at the U3/R junction. Reactivation of viral
expression in YR2 cells by the phorbol 12-myristate
13-acetate (PMA) plus ionomycin combination was
accompanied by a rapid but transient chromatin re-
modeling in the 50-LTR, leading to an increased PU.1
and USF-1/USF-2 recruitment in vivo sustained by
PMA/ionomycin-mediated USF phosphorylation. In
contrast, viral expression was not reactivated by
PMA/ionomycin in L267 cells, because the 50-LTR
U3/R region remained inaccessible to nucleases
and hypermethylated at CpG dinucleotides.
Remarkably, we elucidated the BLV 50-LTR chroma-
tin organization in PBMCs isolated from BLV-
infected cows, thereby depicting the virus hiding
in vivo in its natural host.
INTRODUCTION
Bovine leukemia virus, a B-lymphotropic oncogenic
deltaretrovirus structurally and biologically closely
related to human T-lymphotropic leukemia/lymphoma
virus (HTLV-I) (1–4), is the etiologic agent of a chronic
lymphoproliferative disease termed enzootic bovine
leukosis (4–6). While the majority of infected animals
remain lifelong clinically asymptomatic carriers,  30%
of BLV-infected cattle develop persistent lymphocytosis
(PL) and <5% will be diagnosed with B-cell leukemia/
lymphoma after a long period of latency (7–9) associated
with a lack of viral expression (10). Latency represents a
viral strategy to escape from the host immune system and
likely allows for tumor progression (11).
Viral transcription initiates at the U3/R junction in the
50-long terminal repeat (50-LTR) and is regulated by
cellular transcription factors binding to the 50-LTR, by
the viral transactivating TaxBLV protein and by the
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cis-acting elements located in the 50-LTR have been pre-
viously described, including the promoter CAAT and
TATA boxes (12), a glucocorticoid responsive element
(GRE) (13–16), a PU.1/Spi-B site (17) and three TxREs
(TaxBLV Responsive Elements) in the U3 region, an
upstream stimulatory factor (USF)-binding site termed
E-box4 in the R region (18) and an interferon regulatory
factor (IRF)-binding site in the U5 region (19). TaxBLV-
mediated transcriptional transactivation requires the
U3 TxREs, composed of an imperfectly conserved
cyclic-AMP-responsive element (CRE), which has been
demonstrated to bind CRE-binding protein (CREB),
ATF-1 and -2 (activating transcription factor) and CRE
modulator t (CREMt) isoforms (20–23), and of an E-box
homologous motif overlapping this CRE-like motif
(16,24).
During retroviral infection, the RNA viral genome is
retrotranscribed into a double-stranded complementary
DNA, which becomes integrated into the host cell
genome and organized into chromatin as are all cellular
genes. In eukaryotic cells, genomic DNA is packaged in
condensed 30-nm ﬁbers whose structural and functional
repeating unit, termed nucleosome, consists in 146bp of
DNA tightly wrapped in 1.65 superhelical turns around an
octamer composed of two molecules of each of the four
core histones (H2A, H2B, H3 and H4) (25). Each nucleo-
some is linked to the next by small segments of linker
DNA, and the polynucleosome ﬁber can be stabilized by
the binding of histone H1. Once integrated, BLV provirus
expression relies on chromatin accessibility to cellular
and viral transactivating factors (26,27), and therefore
depends on epigenetic marks such as histone tail
posttranslational modiﬁcations (28,29) and DNA methy-
lation (30). In this agreement, our laboratory and others
have previously reported the importance of histone acetyl-
ation for TaxBLV-dependent and -independent BLV tran-
scriptional regulation (31–34). Furthermore, latency has
been associated with histone hypoacetylation (35) and
more recently DNA CpG methylation (36) in the
50-LTR region of a lymphoma-derived BLV-infected cell
line L267.
Here, we studied the nucleosomal organization of the
BLV 50-LTR in two latently-infected cell lines and in
PBMCs isolated from BLV-infected cows. We described
the epigenetic modiﬁcations associated with latency and
their alteration kinetics following transcriptional activa-
tion of BLV expression by PMA/ionomycin, one of the
most potent activators of viral expression. Finally, we
pointed out the importance of the PU.1/Spi-B and
E-box4-binding sites located in the BLV 50-LTR for the
PMA/ionomycin-mediated transcriptional activation.
MATERIALS AND METHODS
Cell lines and cell culture
The Epstein Barr virus-negative B-lymphoid cell line
DG75 was maintained in RPMI 1640-Glutamax I
medium supplemented with 10% fetal bovine serum
(FBS), 50mg of streptomycin/ml and 50 U of penicillin/ml.
YR2 is a cloned B-lymphoid cell line established from
peripheral blood lymphocytes (PBLs) isolated from a
BLV-infected sheep (37), containing a single monoclonally
integrated mutated silent provirus (8,9), and was main-
tained in Opti-MEM-Glutamax I medium supplemented
with 10% FBS, 50mg of streptomycin/ml and 50U of
penicillin/ml. L267 is a clonal lymphoma-derived B-cell
line established from a BLV-infected sheep (S267)
injected with naked proviral DNA of an infectious BLV
variant (38), whose provirus displays a wild-type sequence
(11,35). L267 cells were maintained in Opti-MEM medium
supplemented with 10% FBS, 1mM sodium pyruvate,
2mM glutamine, non-essential amino acids and 100mg
kanamycin. All cells were grown at 37 C in an atmosphere
of 5% CO2.
Animals
The BLV-seropositive adult cows (BKL-2 (39) and 1267,
named cow1 and 2, respectively) affected with PL were
housed under controlled conditions at the National
Veterinary Research Institute (Pulawy, Poland). PBMCs
from these cows were isolated and cultured as previously
described (18,32).
PMA/ionomycin treatment
Optimal concentrations in B-lymphoid cell lines were
determined as 200nM PMA and 565nM ionomycin
(Sigma Aldrich).
Plasmid constructs
The episomally replicating plasmid pLTR*wt-luc was
described previously (32) and contains the luciferase
gene under the control of the complete 50-LTR of the
344 BLV provirus [strain 344 is an infectious and patho-
genic molecular clone (38)]. The non-episomal pLTR-luc-
derivatives mutated in transcription factor-binding sites
located in the 50-LTR (individually or in combination)
were generated using the QuickChange site-directed mu-
tagenesis kit (17,18,32). The BglII/NheI mutagenized
fragment was introduced into the unique BglII/NheI
sites of the pREP10 (Promega).
Indirect end-labeling technique
The indirect end-labeling (IEL) experiments were per-
formed as previously described (40–43) with minor modi-
ﬁcations. Each size marker was generated by digesting
BLV DNA [using the pBLV344, containing the 344 BLV
strain (9,38)] with two restriction enzymes: the same
enzyme used to digest the samples, namely BamH1, and
another enzyme chosen to generate a fragment of deﬁned
size: AvrII (size of the fragment: 2017nt, marker a), NaeI
(1851nt, b), PmlI (1652nt, c), BsaI (1515nt, d), BssHI
(1339nt, e), NcoI (1251nt, f), KasI (1145nt, g), BanI
(996nt, h), CellII (778nt, i), HincII (639nt, j) or EaeI
(511nt, k). A probe spanning a region downstream of
the BLV 50-LTR [corresponding to nucleotides 1422–
2038, according to (2) and termed BamH1 probe] was
labeled as previously described (40). At the end of the
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calculated according to length marker standard curves.
RNA puriﬁcation and analyze of transcripts
Total RNA was extracted and quantiﬁed as previously
described (36). Initiated and elongated transcripts were
detected with the 50-LTR primers (FW: 50-GAGACCCT
CGTGCTCAGCT-30; RV: 50-CAGAAGGTCTCGGGA
GCAA-30) and the Tax/Rex primers (FW: 50-AAGCCT
TCAAATGCCCAAAG-30; RV: 50-CCCCCAACCAAC
AACACTT-30), respectively. USF-1, USF-2 and PU.1
transcripts were detected with the following pairs of
primers: (i) FW: 50-GGTTGTCTGAAGAACTGC
AGGG-30; RV: 50-TCGTAGCAGCAGATTCTTGTTC
TTA-30; (ii) FW: 50-TCCAGCTTTCAAAAATCATTCC
A-30; RV: 50-GCCTTTGACAGGATCCCTCC-30; and
(iii) FW: 50-CAGCGACCATTACTGGGACTTT-30;
RV: 50-CTCAAACTCGCTGTGCACGT-30. Ovine
b-actin mRNA copies were used to normalize the results
(FW: 50-TCCACTGCTCCTGTCTTCGA-30; RV: 50-GA
TCTTTTCCCGTCCCAAAGT-30).
Transient transfection and luciferase assays
DG75 cells were transfected by electroporation as
described previously (18). At 24h post-transfection, cells
were mock treated or treated with PMA/ionomycin. At
24h post-induction, cells were lysed and assayed for
luciferase activities. Fireﬂy luciferase activities derived
from the BLV promoter were normalized with respect to
the Renilla luciferase activities using the DualGlo-
luciferase reporter assay system (Promega), and to
protein concentrations using the Bradford methodology
(44). Statistical analyses of the data were performed by
one-way ANOVA and P-values are indicated in the
ﬁgure legends.
Electophoretic mobility shift assays
Nuclear extracts were prepared using a protocol described
by Dignam et al. (45). The DNA sequences of the
coding strand of the oligonucleotides used as probes
were as follows (the transcription factor-binding site is
underlined): PU.1/Spi-B probe (50- CCCCAACTTTCCC
CTTTCCCGA-30) and E-box4 probe (50- AGCTACCGT
CTCCACGTGGACTCTCT-30). Electophoretic mobility
shift assays (EMSAs) were performed as described previ-
ously (36).
Western blotting
Nuclear extracts (50mg) from BLV-infected cells, treated
or not with 0.025–0.070 unit of potato acid phosphatase
type VII (Sigma, P0157-25UN)/mg of protein, were
separated by SDS–PAGE and transferred onto
polyvinylidene diﬂuoride (PVDF) membranes. The mem-
branes were then blocked in Tris-buffered saline (TBS)
containing 5% non-fat dry milk and incubated with an
antibody directed against USF-1 (sc8983), USF-2 (sc861)
or PU.1 (sc352). A horseradish peroxidase-conjugated
goat anti-rabbit IgG was used for enhanced chemilumin-
escence detection (Cell Signaling).
Chromatin immunoprecipitation assays
Chromatin immunoprecipitation (ChIP) assays were per-
formed as previously described (46,47) with minor modi-
ﬁcations. To detect chromosomal ﬂanking regions, pellets
were sonicated to obtain DNA fragments of an average
size of 500–800bp. The antibodies used here were directed
against USF-1 (sc8983), USF-2 (sc861), PU.1 (sc352),
RNA polymerase II (sc899), AcH4 (Upstate 06-866),
trimethylH3K4 (04-745), trimethylH3K9 (07-442),
HDAC-1 (sc7872) and a puriﬁed IgG (I-1000, Vector
Laboratories) that was used as a control for immunopre-
cipitation to test non-speciﬁc binding to the plate.
Quantitative real-time PCR reactions were performed
using the MesaGreen qPCR mastermix (Eurogentec)
with 5ml of the eluted DNA product. Relative quantiﬁca-
tion using the standard curve method was performed for
each primer pair and 96-well Optical Reaction plates were
read in an Applied Biosystems AbiPrism 7300 real-time
PCR instrument. Fold enrichments were calculated as per-
centages of input values. Primer sequences used for quan-
tiﬁcation in the E-box4 region (FW: 50-CCTCTGACCGT
CTCCACGT-30; RV: 50-AAGTAAGACAGGAAACAA
GCGC-30) and in an unrelated viral region corresponding
to the env gene (FW: 50-CCTGCGCATTCAAAATGA
CT-30; RV: 50-AGGAACAGGCTTAGAACAGAATG
A-30) were designed using the software Primer Express
2.0 (Applied Biosystems).
RESULTS
Nucleosomal organization of the BLV 50-LTR region
We studied the chromatin organization of the BLV
50-LTR region by the indirect end-labeling technique in
two latently infected cell lines: YR2 and L267. YR2 cells
are considered to be a model for defective latency as two
E- to K- amino acid substitutions in the protein TaxBLV
impair the infectious potential of the integrated provirus
(8,9), whereas L267 cells are infected by a transcriptionally
silent but replication-competent provirus, thereby
constituting a model for true latency (35,38). Nuclei
from these two cell lines were digested with increasing
concentrations of DNase I. After puriﬁcation, DNA was
digested in vitro with the endonuclease BamHI and the
double restriction products were analyzed by Southern
blotting with the BamH1 probe (Figure 1C), spanning nu-
cleotides 1422–2038 of the BLV genome, by where
nucleotide +1 corresponds to the transcriptional start
site located at the U3/R junction in the 50-LTR.
Three regions were found to be preferentially digested in
the 50-LTR of the YR2 provirus (as indicated by arrows in
Figure 1A) and were termed hypersensitive site HS1, HS2
and HS3 (present as a doublet composed of HS3a and
HS3b). By using the size markers as references, we
mapped these DNase I-hypersensitive sites to nucleotides
 183 to  90 (HS1), nucleotides 20–66 (HS2), nucleotides
193–295 and nucleotides 336–374 (HS3a and HS3b), re-
spectively (values averaged from three independent experi-
ments, with a standard deviation of 20nt). Therefore, HS1
and HS2 were respectively associated with the U3 region
Nucleic Acids Research, 2011,Vol.39, No. 22 9561and the beginning of the R region of the BLV 50-LTR,
whereas the third HS was located around the R/U5
junction (Supplementary Figure S1). In contrast, in the
true latent L267 provirus, we observed a single HS
present as a doublet mapping to nucleotides 221–283
and nucleotides 319–372 (Figure 1B) and termed HS3a
and HS3b since it covered the same region as the corres-
ponding HS3a and HS3b in the YR2 provirus. In vitro
DNase I treatment of naked genomic DNA (in conditions
that generated levels of digestion comparable to those
obtained in the in vivo experiments) showed no preferen-
tial cutting in the BLV genome (Figure 1A and B), thereby
indicating that the HS observed in vivo were the direct
consequence of chromatin organization and not secondary
to sequence-directed cleavage preference by DNase I.
Noteworthy, the different BLV provirus integration site
in the host cell genome of YR2 and L267 cells could
explain the cutting differences observed upstream of the
proviruses.
Altogether, these results demonstrate the presence of a
constitutive DNase I-hypersensitive site in the R/U5
region, whereas the accessibility of the U3/R junction
depends on the cell system used. These data were con-
ﬁrmed using micrococcal nuclease (MNase) which cuts
in both nucleosome-free regions of chromatin and linker
regions between nucleosomes (Figure 1D). In these experi-
ments, we observed in both cell lines a discrete banding
pattern (indicated by arrowheads on Figure 1D) corres-
ponding to an approximate 160-bp nucleosome ladder,
thereby reﬂecting a precise nucleosome positioning in
this chromatin region in all integrated copies of the BLV
provirus. Moreover, three MNase-hypersensitive sites
were detected in the YR2 cell line, spanning nucleotides
 170 to  113 (HS1), nucleotides  1 to 40 (HS2) and nu-
cleotides 194–261 and nucleotides 294–359 (HS3a and
HS3b) (values averaged from three independent experi-
ments, with a standard deviation of 15bp). These
MNase hypersensitive sites were thus mapping the same
Figure 1. Mapping of DNase I- and MNase-hypersensitive sites (HS) in the BLV 50-LTR in two latently infected cell lines YR2 and L267. (A and B)
Nuclei from YR2 (A) and L267 (B) cells were digested with increasing concentrations of DNase I (0, 10, 20, 30, 40, 45, 50, 55U/ml and 0, 80, 90,
100, 120U/ml, respectively; the high doses of DNase I used in L267 cells compared to those used in YR2 cells account for the lowest increase in
nuclease hypersensitivity observed upon increasing concentrations of DNase I) and examined by indirect end-labeling following BamH1 digestion
in vitro (lanes 1–8 and 1–5, respectively). Naked DNA puriﬁed from each cell line was digested in vitro by DNase I as a control (lanes 9–12 and 6–9,
respectively). HS are indicated by arrows. Size markers were described in the ‘Materials and Methods’ section. The Figure shows one representative
experiment from three independent IEL assays. (C) Schematic representation of the BamH1 probe (nucleotides 1422–2038) used in our indirect
end-labeling experiments. (D) Nuclei from YR2 and L267 cells were digested with increasing concentrations of micrococcal nuclease (MNase; 0, 15,
30, 40, 50, 60, 80, 90 and 100 10
 2U/ml and 0, 15, 30, 60, 100 and 120 10
 2U/ml, respectively) and examined by indirect end-labeling following
BamH1 digestion in vitro (lanes 1–9 and 15–20, respectively). Naked DNA puriﬁed from each cell line was digested in vitro by MNase as a control
(lanes 10–14 and 21–23, respectively). The molecular weight markers were described in the ‘Materials and Methods’ section. HS are indicated by
arrows; arrowheads indicate a discrete banding pattern corresponding to  160-bp nucleosome ladder. The Figure shows one representative experi-
ment from three independent IEL assays.
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sites. Remarkably, we detected only one major MNase-
hypersensitive site in the L267 cell proviral 50-LTR,
spanning nucleotides 201–276 and nucleotides 291–373
for the HS3a and HS3b, respectively. As a control,
in vitro digestion of naked DNA from YR2 or L267
cells under the same conditions showed no speciﬁc
proﬁle of digestion in the BLV 50-LTR, thereby indicating
that the pattern observed was secondary to chromatin
organization.
Importantly, we also elucidated by indirect end-labeling
the chromatin structure of the BLV 50-LTR in peripheral
blood mononuclear cells (PBMCs) isolated from two
BLV-infected cows presenting PL (Figure 2). PBMCs
removal from immune plasma followed by ex vivo
culturing have been shown to induce a transition from
latent to productive viral state attributed to the presence
of lymphocyte activators (such as fetal calf serum, lipo-
polysaccharides, etc.) in the culture medium (10,48).
Nearly similar to what we observed in YR2 cells, the
50-LTR nucleosomal organization of the integrated
provirus reﬂected an open chromatin conﬁguration as
demonstrated by an increased accessibility to DNase I
both between HS1 and HS2 (mapped to nucleotides
 187 to 35) in the U3/R region and in the HS3
(mapped to nucleotides 173–303) in the R/U5 region
(Figure 2).
Based on these results, we established a map of nucleo-
some position in the BLV 50-LTR region (Supplementary
Figure S1). The U3/R junction region harbored a closed
chromatin conﬁguration and was previously reported by
our laboratory (36) to be hypermethylated at CpG di-
nucleotides in the L267 true latent provirus, whereas it
was more accessible to nucleases and hypomethylated in
YR2 defective latent provirus. The HS3 region,
overlapping the end of the R and the U5 regions, was
constitutively accessible and separated from the U3
region by a single nucleosome (termed nuc-1) located
immediately downstream of the transcription start site
(around nucleotides 47–197; Supplementary Figure S1).
These results suggest that DNA methylation and a
closed chromatin conﬁguration in the 50-LTR U3/R
junction region might collaborate in repressing BLV ex-
pression in vivo, therefore promoting viral escape from
the host immune system and tumor development. In
agreement, viral productive state in PBMCs from
BLV-infected cows is associated with open chromatin in
the 50-LTR U3/R region.
PMA/ionomycin-mediated transient disruption of the BLV
promoter chromatin organization
We next compared the nucleosomal structure of the BLV
50-LTR in basal versus activated conditions following
treatment of the cells with the PMA (a phorbol ester)
plus ionomycin (a calcium ionophore) combination, a
potent activator of BLV expression ex vivo (49). Nuclei
from mock treated or PMA/ionomycin-stimulated (for
30–60min) YR2 and L267 cells were digested with six dif-
ferent restriction endonucleases cutting at 13 distinct sites
within the BLV promoter region (Figure 3C). The
obtained restriction fragments were analyzed by
Southern blotting using the BamH1 probe (Figure 3A
and B).
PMA/ionomycin treatment of YR2 cells provoked a
marked increase in chromatin accessibility to certain
endonucleases cutting in two distinct regions of the BLV
50-LTR (Figure 3A). The enhanced sensibility to KasI
(band , nucleotide  195), HaeII (band , nucleotide
 182), DrdI (band , nucleotide  148) in the HS1 and to
AvaI (band , nucleotide  59) in the closed chromatin
region between HS1 and HS2 under basal condition
(based on the predictions made from our DNase I and
MNase IEL experiments) indicated that HS1 became
more open and extended at its 30 boundary (from nucleo-
tide  102 to at least nucleotide  59) following PMA/
ionomycin treatment of YR2 cells (Figure 3C).
Moreover, the increased cutting by BsaWI (nucleotide
153) was compatible with an extent of the HS3a at its 50
Figure 2. Chromatin organization of the 50-LTR in PBMCs from BLV-infected cows. Nuclei from PBMCs of two BLV-infected cows presenting PL
were digested by increasing concentrations of DNase I (from 0 to 50U/ml) and analyzed by indirect end-labeling following BamH1 digestion in vitro.
As a control, YR2 nuclei digested by DNase I (70U/ml) were run on the same gel (lane 1). HS are indicated by brackets. The Figure shows one
representative experiment from three independent IEL assays.
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following this treatment (Figure 3A and C). Because AvaI
and KasI cut at other sites (bands*; nucleotide 49 and 277,
respectively) at the same rate in mock-treated and PMA/
ionomycin-treated YR2 cells, the enhanced digestions
described above are likely to be a direct consequence of
an increased chromatin accessibility. Moreover, none of
the restriction enzymes tested was able to cut in the U3
region of the L267 provirus [KasI (nucleotide  195),
HaeII (nucleotide  182), DrdI (nucleotide  148; nucleo-
tide 76) and AvaI (nucleotide  59); Figure 3B], thereby
conﬁrming the presence of a closed chromatin organiza-
tion in this region of the silent provirus. Upon
PMA/ionomycin stimulation, the L267 U3 region
remained inaccessible to endonucleases, whereas the
HS3a site behaved similarly as in the YR2 cells (i.e.
becoming larger at its 50 boundary; see the BsaWI band
at nucleotide 153; compare Figure 3A and B). We con-
ﬁrmed these results by showing that DNase I hypersensi-
tivity was increased in the HS1 and HS3, but not in the
HS2, upon PMA/ionomycin stimulation of YR2 cells
(Supplementary Figure S2A). Moreover, the U3/R
junction region of the BLV 50-LTR remained inaccessible
to nucleases in L267 cells after PMA/ionomycin stimula-
tion, while the HS3 was sensitive to this treatment
(Supplementary Figure S2A).
Figure 3. PMA/ionomycin-mediated disruption of the chromatin organization within the BLV promoter region. Nuclei from YR2 (A) or L267 (B)
cells mock treated or treated with PMA/ionomycin (for 30 or 60min) were digested by restriction enzymes (HaeII, DrdI, AvaI, BsaWI, BsaHI and
KasI) and examined by indirect end-labeling following BamH1 digestion in vitro. When several restriction sites for the same enzyme were found
within the region under study, symbols were used (open circle, asterisks, dollar and hash) to differentiate them. The Figure shows one representative
experiment from three independent IEL assays. (C) Schematic representation of HS positions in the YR2 and L267 50-LTR (solid bars) and of the
regions which became accessible following PMA/ionomycin stimulation (indicated by arrows). Positions of restriction sites of interest and of the PU.1
an E-box 4-binding sites are indicated.
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PMA/ionomycin-mediated effects on both transcriptional
activation of viral expression and chromatin disruption in
the BLV promoter. YR2 and L267 cells were mock treated
or treated with PMA/ionomycin for different periods of
time (15, 30, 60, 90 and 120min). Both initiated and
elongated BLV transcripts were measured by RT–qPCR
using primers speciﬁc to either the 50-LTR (reﬂecting the
amount of initiated transcripts) or the Tax/Rex transcripts
(reﬂecting the amount of elongated transcripts). PMA/
ionomycin treatment of L267 cells did not activate viral
transcription (Figure 4A) in agreement with its inability to
open chromatin in the U3/R junction region (Figure 3B)
and to modify the CpG hypermethylated DNA proﬁle of
the BLV 50-LTR observed in these cells as demonstrated
by our bisulﬁte sequencing analyses (Supplementary
Figure S2B). In contrast, PMA/ionomycin stimulation of
YR2 cells induced a transient increase in BLV gene ex-
pression, reaching its maximum at 60min post-treatment
for initiated transcripts and at 90min post-treatment for
elongated ones (Figure 4A). In parallel, we quantiﬁed the
kinetics of chromatin remodeling following PMA/
ionomycin stimulation of these cells by using restriction
enzymes cutting in the regions of interest: DrdI (band ,
nucleotide  148) and HinfI (band , nucleotide  112),
allowing to study the HS1 or BsaWI (nucleotide 153)
and HinfI (band*, nucleotide 180), allowing to study the
HS3 (Figure 4B and C). A marked increase in chromatin
accessibility in the HS1 region was noted as rapidly as
15min post-treatment and peaked at 30min post-
treatment (HinfI  and DrdI ), whereas maximal accessi-
bility of the HS3a extent peaked at 60min post-induction
(BsaWI). The unaffected proﬁle of another HinfI-
generated band (band*, located in a constitutively access-
ible region of the HS3a) following PMA/ionomycin treat-
ment demonstrated the speciﬁcity of the chromatin
disruption we identiﬁed here. The chromatin remodeling
observed was independent of both replication and tran-
scription. Indeed, on one hand, cell cultures were not
synchronized and presented a doubling time of  24h
and, on the other hand, chromatin remodeling preceded
viral transcriptional activation (HS were already partly
remodeled at 15min after induction, while transcription
was only activated after 60min post-treatment based on
viral mRNA quantiﬁcation).
Altogether, these results show a PMA/ionomycin-
mediated transient disruption in the chromatin organiza-
tion of the BLV 50-LTR, allowing a maximal opening of
the HS1 at 30min post-treatment accompanied by the ac-
tivation of viral expression and a 50 extent of the HS3a
peaking at 60min after stimulation but not sufﬁcient to
allow efﬁcient transcription.
The PU.1/Spi-B and E-box4 motifs located in the BLV
50-LTR are important for its PMA/ionomycin-inducible
transcriptional activity
Several transcription factors binding in the BLV 50-LTR
could play a role either for the stabilization of a closed
chromatin conﬁguration in basal condition or for the nu-
cleosomal disruption and/or transcriptional activation we
observed following PMA/ionomycin stimulation. We
studied the effects of mutations abolishing respective
factor binding to the CRE1, CRE2, CRE3, CRE1+2+3
(32), E-box1+2+3 (32), PU.1/Spi-B (17), GRE (32),
E-box4 (18) and IRF (18,50) motifs of the BLV 50-LTR
(Supplementary Figures 3SA and B) on both basal and
activated BLV transcriptional activity. We transiently
transfected wild-type and mutated LTR-reporter
episomal constructs in the human B-lymphoid cell line
DG75. In these experiments, we used episomally
replicating constructs as they have been previously
shown to display hallmarks of proper chromatin structure
when transiently transfected into cells (51,52).
Twenty-four hours post-transfection, cells were mock
treated or treated with PMA/ionomycin. Twenty-four
hours post-induction, cells were lysed and assayed for
luciferase activity (Supplementary Figure S3). The BLV
promoter basal transcriptional activity strongly decreased
when each of the three CRE was mutated (reaching a
60.1% decrease for the combinatorial mutant; see
Supplementary Figure S3A), whereas mutations in the
PU.1/Spi-B, GRE, E-box4 and IRF motifs located down-
stream of the transcription start site caused a less marked
reduction of basal transcription (Supplementary Figure
S3A).
Upon PMA/ionomycin stimulation, we observed a
10.8-fold induction of the wild-type BLV promoter tran-
scriptional activity (Supplementary Figure S3B), which
was affected by mutation in the PU.1/Spi-B motif
(26.2% decrease of the PMA/ionomycin effect) and in
the E-box4 motif (46.0% decrease) (Figure 5).
Interestingly, the PU.1/Spi-B-binding site (centered at nu-
cleotide  93) is located in the 30 boundary region of the
HS1, which became accessible to nucleases following
PMA/ionomycin stimulation in our IEL experiments,
and the E-box4 motif (centered at nucleotide  175) is
located in the 50 boundary region extent of the HS3a
induced by PMA/ionomycin treatment of the cells
(Figure 3C). However, the IRF-binding site (nucleotide
255), whose mutation caused only a slight decrease
(4.7%) of the PMA/ionomycin-induced transcriptional
activity of the BLV promoter but markedly reduced its
basal activity (40.5% decrease), is located in a constitu-
tively accessible region of the HS3a.
In conclusion, these results demonstrate a role for the
U3 region PU.1/Spi-B-binding site and for the R region
E-box4 motif in the PMA/ionomycin-stimulated activa-
tion of BLV transcription.
PMA/ionomycin-mediated phosphorylation of USF-1 and
-2 modiﬁes their binding afﬁnity for the E-box4 motif
In order to address the potential mechanisms underlying
PU.1 and USF role in the PMA/ionomycin-mediated ac-
tivation of BLV transcriptional activity, we decided to
examine whether these transcription factors have their ex-
pression and/or action modulated by this treatment.
We ﬁrst evaluated the in vitro binding properties of
PU.1 and of USF-1/-2 to their respective DNA-binding
motifs (the PU.1/Spi-B site and the E-box4 motif) in the
BLV 50-LTR. For this purpose, we performed EMSAs
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treated YR2 cells (Supplementary Figure S4 and Figure
6, respectively). In agreement with previous studies (17–
19), we observed the speciﬁc binding of PU.1 to the PU.1/
Spi-B probe and of USF to the E-box4 probe (Figure 6A)
in basal condition. Importantly, PMA/ionomycin
cell treatment induced a rapid and transient increase in
USF binding to the E-box4 motif, culminating at
30–60min after treatment (Figure 6A). Moreover,
supershift analyses of the USF-1/USF-2 retarded complex
in the absence or presence of PMA/ionomycin did not
reveal any change in this complex composition following
stimulation (Figure 6A). However, we observed no in-
crease in PU.1 binding to the PU.1/Spi-B probe
Figure 4. (A) PMA/ionomycin reactivates viral transcription in YR2 cells, but not in L267 cells. Total RNAs from YR2 and L267 cells mock treated
or treated with PMA/ionomycin during different periods of time (15, 30, 60, 90 and 120min) were used in RT–qPCR using primers targeting either
the BLV 50-LTR or Tax/Rex transcripts. Results are presented as histograms indicating the PMA/ionomycin induction (n-fold) with respect to the
mock-treated mRNA level, which was arbitrarily attributed a value of 1. Each value is the mean±SEM of three independent experiments performed
in triplicate. (B and C) Kinetics of the chromatin disruption observed in YR2 50-LTR following PMA/ionomycin stimulation (B) Nuclei from YR2
cells mock treated or treated with PMA/ionomycin (for 15, 30, 60, 90 and 120min) were digested with the endonucleases HinfI, DrdI or BsaWI.
After in vitro digestion with BamH1, samples were analyzed by indirect end-labeling experiments with the BamH1 probe. The Figure shows one
representative experiment from three independent IEL assays. (C) Quantiﬁcation of the bands was performed by radioimaging analysis using an
InstantImager (Packard). Results are presented as curves indicating the band intensities relative to that observed with mock-treated cells, which was
arbitrarily assigned a value of 1. Results represent the average from three independent IEL experiments.
9566 Nucleic Acids Research, 2011,Vol.39, No. 22(Supplementary Figure S4A), thereby suggesting that the
effect observed for the USF-1/-2 complex was speciﬁc to
these transcription factors.
We next measured the PU.1 and USF mRNA and
protein expression levels following PMA/ionomycin
stimulation, in order to check whether increased viral ex-
pression resulted from an increase in transcription factors
availability in the cells. Total RNA and nuclear extracts
from YR2 cells mock treated or treated with PMA/
ionomycin for different periods of time (15, 30, 60, 90
and 120min) were used in RT–qPCR and in western
blot experiments to measure PU.1 and USF-1/-2 mRNA
expression levels and to assess their protein expression
levels, respectively. PMA/ionomycin did not affect PU.1
(Supplementary Figure S4B and C), USF-1 or USF-2
(Figure 6B and C) mRNA and protein expression levels.
Interestingly, by western blot experiments, we detected a
second form of the USF protein appearing at 15min
post-induction (Figure 6C). It has been previously
reported in the literature that western blotting analysis
of both USF-1 and USF-2 isolated from nuclear extracts
allowed the detection of an additional band with slower
mobility corresponding to the phosphorylated form of the
proteins (53). In order to assess whether the additional
band observed here corresponded to phosphorylated
USF, nuclear extracts from YR2 cells stimulated or not
with PMA/ionomycin for 30min were treated with
increasing amounts of potato acid phosphatase. This
treatment led to a dose-dependent decrease of the intensity
of the 44-kDa band of the USF-1 protein, thereby con-
ﬁrming that it corresponded to its phophorylated form
(Figure 6D). We tested the effect of several speciﬁc inhibi-
tors of different signaling pathways known to lead to USF
phosphorylation, including inhibitors of p38, JNK (c-Jun
N-terminal Kinase), ERK (Extracellular-Regulated
Kinase) and the cyclin-dependent kinases p34
cdk1/
cyclinB and p33
cdk2/cyclinA. However, we could not
identify the kinase responsible for the USF phosphoryl-
ation event resulting from PMA/ionomycin treatment of
the cells (data not shown).
Importantly, we demonstrated that USF phosphoryl-
ation was necessary for its PMA/ionomycin-induced
binding to the BLV 50-LTR E-box4 motif as potato acid
phosphatase treatment of nuclear extracts used in EMSAs
impaired PMA/ionomycin-induced USF DNA-binding
activity in a dose-dependent manner (Figure 6E).
Altogether, these results demonstrate that PMA/
ionomycin stimulation of B-lymphoid cells induces USF
phosphorylation, a post-translational modiﬁcation neces-
sary to increase its DNA-binding afﬁnity for the E-box4
motif.
PMA/ionomycin-induced chromatin remodeling in the
BLV 50-LTR reaches its maximal level before the
increase in PU.1 and USF recruitment
We further investigated the kinetics of PMA/ionomycin-
mediated chromatin remodeling by performing ChIP
assays on the BLV 50-LTR region in order to assess
the alterations in the level of several epigenetic marks
(H4 acetylation, H3K4 trimethylation and H3K9
trimethylation) and in the in vivo recruitment of the
Figure 5. The PU.1/Spi-B and E-box4 motifs located in the BLV 50-LTR are important for its PMA/ionomycin-stimulated transcriptional activity.
DG75 cells were transiently transfected by electroporation with 8mg of pLTR*-luc-derived constructs and 50ng of pRL-TK (Promega). Cells were
mock treated or treated with PMA/ionomycin 24h after transfection. Luciferase activities (ﬁreﬂy and Renilla) were measured in cell lysates 48h after
transfection. Results are presented as histograms indicating PMA/ionomycin-mediated induction (n-fold) of pLTR*-luc-derivative constructs with
respect to their respective basal activities and compared to the pLTR*wt-luc, which was assigned a value of 100%. Each value is the mean±SEM of
three separate experiments performed in triplicate. *P<0.05, **P<0.1 and ***P<0.5 compared to the wild-type construct pLTR*-luc, as assessed
by one-way ANOVA.
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purpose, chromatin prepared from YR2 cells mock-
treated or treated with PMA/ionomycin for different
periods of time (15, 30, 60, 90 and 120min) was
immunoprecipitated with speciﬁc antibodies or with a
non-speciﬁc IgG antibody as a control. Puriﬁed DNA
was then ampliﬁed with oligonucleotide primers
hybridizing in the BLV 50-LTR or in an unrelated region
corresponding to the BLV env gene. Because the size of
the fragments obtained after sonication approximated
500–800bp, it was not possible to distinguish the
PU.1-binding site located in the HS1 from the E-box4
motif located in the HS3a.
As shown in Figure 7A, we observed a rapid and tran-
sient increase in histone H4 acetylation and H3 lysine 4
(H3K4) trimethylation levels, two chromatin marks
associated with active transcription, in the BLV 50-LTR
region following PMA/ionomycin stimulation. In
contrast, H3K9 trimethylation, a repressive mark
associated to transcriptional silencing and heterochroma-
tin regions, rapidly decreased in the BLV 50-LTR region
following PMA/ionomycin stimulation. The histone
deacetylase HDAC-1 has been previously demonstrated
to be recruited to the BLV 50-LTR in latent conditions
(35). Here, we observed that HDAC-1 recruitment was
inversely correlated to H4 acetylation level in the viral
promoter region (Figure 7A). The transient nature of the
increased level in chromatin marks associated with tran-
scriptionally active genes, in correlation with HDAC-1 re-
cruitment proﬁle, suggested that remodeled chromatin
Figure 6. PMA/ionomycin-induced phosphorylation of USF increases its DNA-binding afﬁnity for the BLV E-box4 motif. (A) EMSAs were per-
formed with nuclear extracts from YR2 cells mock treated or treated with PMA/ionomycin for different periods of time and a radiolabeled probe
corresponding to the BLV E-box4 motif. Nuclear extracts from mock- or PMA/ionomycin-treated (for 30min) YR2 cells were used in supershift
experiments with the E-box4 radiolabeled probe alone or with an antibody directed against USF-1 or USF-2. A second not yet identiﬁed complex
binding to the same probe was presented as a loading control. (B) USF-1 and USF-2 mRNA expression levels in mock- versus PMA/
ionomycin-treated YR2 cells were measured by RT–qPCR. Results are presented as histograms indicating the PMA/ionomycin induction (n-fold)
with respect to the mock-treated mRNA level, which was arbitrarily attributed a value of 1. Each value is the mean±SEM of two independent
experiments performed in triplicate. (C) Nuclear extracts from (A) were used in western blot experiments to detect USF-1 and USF-2 protein
expression levels. As a loading control, the membrane was stained with Coomassie blue. (D) Nuclear extracts from mock- or PMA/ionomycin-treated
YR2 cells were treated or not with increasing concentrations of potato acid phosphatase, resolved by SDS–PAGE and analyzed by immunoblotting
with an antibody directed against USF-1. (E) Nuclear extracts from (D) were used in EMSAs experiments with the E-box4 radiolabeled probe.
9568 Nucleic Acids Research, 2011,Vol.39, No. 22Figure 7. Chromatin remodeling precedes the increase in transcription factors recruitment to the BLV 50-LTR in YR2 cells. Chromatin prepared
from untreated or PMA/ionomycin-treated YR2 cells (for 15, 30, 60, 90 and 120min) was immunoprecipitated with speciﬁc antibodies directed
against chromatin marks or chromatin modiﬁcation enzymes (A), transcription factors and RNA polymerase II (B) or with an IgG antibody as a
control. Puriﬁed DNA was then ampliﬁed with oligonucleotide primers hybridizing in the BLV 50-LTR (upper panel for each antibody) or in an
unrelated region corresponding to the BLV env gene (down panel for each antibody). Results are presented as histograms indicating percentages of
immunoprecipitated DNA/input DNA (% IP/In). The ﬁrst bar corresponds to IgG control and the second bar to the indicated speciﬁc antibody.
Data are the mean±SEM of triplicate samples from one representative of three independent experiments.
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our IEL results.
USF-1 and USF-2 were recruited to the BLV 50-LTR in
a way similar to their kinetics of increase in DNA-binding
afﬁnity for the E-box4 motif observed in EMSAs follow-
ing PMA/ionomycin stimulation (Figure 7B). PU.1 in vivo
recruitment to the 50-LTR rapidly increased, attaining its
maximum at 15min post-treatment, whereas USF recruit-
ment peaked at 30–60min post-stimulation. However,
PU.1 recruitment was not affected by PMA/ionomycin
in the L267 50-LTR, where the HS1 region remained in-
accessible to nucleases after stimulation (Supplementary
Figure S5B). These results suggest that PMA/
ionomycin-mediated rapid chromatin opening in the
HS1 region of the YR2 provirus resulted in an increased
access to this region for transcription factors, thereby
allowing a rapid recruitment of PU.1. RNA polymerase
II was recruited in a way similar to USF, peaking at
60min post-treatment. However, additional experiments
using shorter periods of PMA/ionomycin treatment (5
and 10min) did not allow us to afﬁrm that chromatin
opening occurs before transcription factors recruitment.
Indeed, both chromatin opening and a slight increase in
USF and PU.1 in vivo recruitment were already observed
at 5min post-induction (data not shown).
We did not observe other major differences between
YR2 cells (Figure 7) and L267 cells (Supplementary
Figure S5), except (i) the absence of increased RNA poly-
merase II recruitment to the env gene in L267 cells, which
is correlated to the absence of transcriptional activity in
these cells; (ii) lower levels of histone marks associated
with actively transcribed genes and higher levels of
H3K9 trimethylation and HDAC-1 occupancy in the
L267 50-LTR compared to YR2 cells. These latter results
are in good agreement with the BLV 50-LTR chromatin
structure we observed in these cells.
In conclusion, these results suggest that PU.1 and USF
transcription factors recruitment that participates in tran-
scriptional activation is increased later in the PMA/
ionomycin time course than the rapidly induced chroma-
tin remodeling observed in the BLV 50-LTR upon PMA/
ionomycin stimulation.
DISCUSSION
BLV latency results from transcriptional repression in vivo
and represents a viral strategy to escape from the host
immune system and likely allows for tumor progression.
Here, we discriminated two types of latency: a ‘locked’
latent state of the L267 provirus and an easily reactivable
latent state of the YR2 provirus.
We showed that the true latent state of the L267
provirus results from a strong epigenetic control where
histone repressive marks and DNA methylation (36) in
the U3/R region of the BLV 50-LTR act in concert to
maintain a closed chromatin conﬁguration. Activation of
the B-cell receptor leads to the activation of the protein
kinase C (PKC) pathway and to an intracellular increase
in Ca
2+ level, which may be mimicked by the PMA plus
ionomycin combined treatment. The locked silent state of
the L267 provirus could not be reversed by PMA/
ionomycin treatment of the cells as we did not observe
neither chromatin opening in the transcriptional
promoter region, nor DNA demethylation of the U3/R
region nor transcriptional activation of viral expression
following this treatment. Although the R/U5 HS3a did
extend at its 50 boundary following stimulation, this was
not sufﬁcient to activate transcription. When transduced
in these cells, the strong viral transactivator TaxBLV
protein has previously been demonstrated to partially
unveil transcriptional repression of viral expression by
allowing a partial demethylation of the U3/R region of
the L267 provirus via an indirect mechanism involving
downregulation of DNMTs expression (36). However, in
this study, TaxBLV was not able to modify the closed chro-
matin conﬁguration of the transcriptional start site region
in the L267 provirus (data not shown).
In the 50-LTR of YR2 cells, whose proviral latency has
been attributed to a mutated inactive TaxBLV protein,
we observed a less closed chromatin conﬁguration,
characterized by the presence of two additional hypersen-
sitive sites in the U3/R region which were absent in the
L267 provirus. Accordingly, we have previously reported
the absence of DNA methylation in the U3/R region of
the YR2 provirus, in opposition to the hypermethylated
state of the L267 provirus corresponding region (36). The
R/U5 region was partially accessible to nucleases in both
models. PMA/ionomycin stimulation allowed transcrip-
tional activation of BLV expression in YR2 cells, which
was associated to a transient chromatin remodeling: the
HS1 region became more accessible to nucleases and
extended at its 30 boundary, whereas the HS3a ex-
tended at its 50 boundary. We established the kinetics of
chromatin disruption, by showing that the HS1 extent
peaked at 30min post-treatment and was followed by
the HS3a remodeling, reaching its maximum at 60min
post-treatment.
Together with these remodeling events, we reported
here an increased (but slightly delayed) accessibility to
DNA for transcription factors to the PU.1/Spi-B motif
located in the HS1 and to the E-box4 motif, previously
shown by our laboratory to bind USF-1 and USF-2 as an
heterodimer (18), located in the HS3a 50 boundary extent.
We also demonstrated that these two motifs are important
for optimal PMA/ionomycin inducibility of viral tran-
scriptional activity by transient transfection experiments.
Mechanistically, we showed by EMSAs that PMA/
ionomycin treatment led to an increased in vitro binding
of the USF-1/USF-2 retarded complex to the E-box4
probe. We identiﬁed posttranslational phosphorylation
of USF as the modiﬁcation responsible for this PMA/
ionomycin-mediated increased DNA-binding afﬁnity.
However, PMA/ionomycin treatment of B cells did not
directly affect PU.1 mRNA and protein expression or its
DNA-binding afﬁnity for the BLV PU.1/Spi-B-binding
site.
We also demonstrated here by ChIP that 50-LTR chro-
matin remodeling peaked at 15–30min post-treatment,
whereas the increased in vivo recruitment of PU.1 and
USF transcription factors and of RNA polymerase II to
the BLV 50-LTR reached its maximum at 30–60min
9570 Nucleic Acids Research, 2011,Vol.39, No. 22post-treatment. We showed that a rapid and transient
increase in H4 acetylation and H3K4 trimethylation
levels was correlated with a decreased H3K9
trimethylation level in the 50-LTR region, supporting the
notion of a rapid but transient chromatin disruption in
response to PMA/ionomycin in YR2 cells, and in agree-
ment with our indirect end-labeling experiments. The
absence of chromatin remodeling in the L267 U3/R
region was accompanied by a lack of increased PU.1 re-
cruitment, suggesting that PU.1 requires the easier access
to DNA offered by chromatin remodeling to be recruited
to the BLV promoter region. Since it was rapidly
phosphorylated after PMA/ionomycin treatment and
already recruited in basal condition to the BLV 50-LTR,
we cannot exclude a potential role of USF in chromatin
opening of the HS3 region. Other not yet identiﬁed tran-
scription factors could also participate to a rapid recruit-
ment of chromatin-modifying enzymes to the BLV 50-LTR
in response to PMA/ionomycin stimulation. The identiﬁ-
cation of these factors, and of the enzyme(s) they are
associated with, would represent a further step in the com-
prehension of viral escape from latency.
The transient nature of the chromatin remodeling
observed in the BLV promoter upon PMA/ionomycin
treatment may rely on the ability of the virus to return
to its latent state by recruiting repressive chromatin-
modifying enzymes such as HDACs (as supported by
the recruitment proﬁle of HDAC-1 to the BLV
promoter, see Figure 7). This chromatin opening may
require the presence of a wild-type TaxBLV to become
permanent, as suggested by our indirect end-labeling ex-
periments showing that TaxBLV ensures an open chroma-
tin organization in the viral promoter of YR2LTaxSN cells
[resulting from the transduction of native YR2 cells with a
retroviral expression vector encoding the wild-type tax
cDNA (8)] (unpublished data from our laboratory).
Importantly, to our knowledge, this study constitutes
the ﬁrst example of determination of the nucleosomal or-
ganization of a retroviral promoter in its naturally infected
host. Indeed, such analyses would be challenging for other
retroviruses such as human immunodeﬁciency virus type 1
(HIV-1) due to the difﬁculty to obtain sufﬁcient amounts
of cells containing a silent integrated form of the provirus
from infected individuals. Here, we analyzed the chroma-
tin organization of the BLV promoter region present in
PBMCs from two infected cows and thereby validated in a
more physiological context the results we obtained with
BLV-infected cell line models.
Altogether, these data depict two kinds of latency of the
BLV provirus: an easily reactivable latent state in the YR2
cells and a locked silent state, resistant to reactivation, in
the L267 cells. Histone posttranslational modiﬁcations
and DNA methylation cooperate to maintain a strong
epigenetic control of the L267 provirus, thereby maintain-
ing BLV transcriptional repression.
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